Biomarker ID | 1121 |
PMID | 23716368 |
Year | 2013 |
Biomarker | Asporin; Cartilage oligomeric matrix Protein (COMP); Versican; EMILIN 3; |
Biomarker Basis | Concentration Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Agressive Prostate Cancer (Fold Change); [Asporin (2.14 fold); Cartilage oligomeric matrix Protein (COMP) (100 fold) ; Versican (100 fold) ; EMILIN 3 ( 6 fold); |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Agressive Vs Non Agressive Prostate Cancer |
Type of Biomarker | Prognostic |
Cohort | Verification Set: 12 Samples from Normal Prostate, 31 from Non Agressive Prostate Cancer and 24 Agressive Prostate Cancer set were chosen for analysis |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | Asporin (p=0.00016) ; Cartilage oligomeric matrix Protein (COMP) (p = 0.00228) ; Versican ( 0.03367) ; EMILIN 3 (0.04983); |
Method Used | Liquid chromatography–mass spectrometry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |